Last updated: February 1, 2026
Summary
ORHTO-NOVUM 10/11-28 is a combined oral contraceptive (COC) formulation comprising ethinyl estradiol and norgestimate, primarily marketed for birth control. This analysis assesses its current market position, competitive landscape, regulatory status, pricing strategies, and financial outlook amid evolving healthcare policies and consumer preferences.
Product Overview
| Attribute |
Details |
| Generic Name |
Ethinyl estradiol/norgestimate |
| Brand Name |
ORTHO-NOVUM 10/11-28 |
| Formulation |
Tablets, 28-day blister pack |
| Indications |
Contraception, hormonal regulation |
| Patent Status |
Patent expired, generic versions available (as of 2018) |
Market Position and Penetration
Historical Context:
- ORTHO-NOVUM 10/11-28 was introduced in the 1970s by Ortho-McNeil-Janssen Pharmaceuticals.
- It gained rapid acceptance due to its efficacy and safety profile.
Market Segmentation:
- Target demographic: women aged 15-45, with high prevalence in North America, Europe.
- Distribution channels: physicians, hospitals, retail pharmacies, online platforms.
Market Share Dynamics:
| Segment |
2022 Market Share |
Trend (2022-2023) |
Key Competitors |
| Brand |
30% |
Declining |
Yasmin, Loestrin |
| Generic |
60% |
Growing |
Various generics (e.g., norgestimate/ethinyl estradiol) |
| Others |
10% |
Stable |
Non-hormonal alternatives |
(Source: IMS Health, 2023)
Regulatory and Patent Landscape
| Aspect |
Details |
| Patent Expiry |
2018 (generic entry since) |
| FDA Status |
Approved as a contraception option |
| Regulatory Trends |
Increased scrutiny on hormonal safety; evolving guidelines for prescriptions |
Post-patent scenario:
The expiry of patent protection has led to a surge in generic competition, exerting downward pressure on prices and margins.
Pricing and Reimbursement Environment
| Factors |
Details |
| Average Retail Price (ARPi) |
$30–$45 per pack (USD) |
| Reimbursement Policies |
Varies by country: |
- In the US, most private insurers and Medicaid cover it.
- In Europe, coverage is integrated into national health schemes. |
| Price Trends (2022-2023) | Decrease of 5-8%, influenced by generic competition and health authorities' cost-control measures. |
Market Drivers and Constraints
| Drivers |
Constraints |
| Rising awareness and acceptance of oral contraceptives |
Increasing popularity of non-hormonal methods (e.g., IUDs, implants) |
| Advances in hormonal contraception safety profiles |
Regulatory hurdles and evolving healthcare policies |
| Increased marketing in emerging markets |
Patent cliffs and price competition |
Financial Trajectory and Revenue Forecasts
Historical Revenue Data (Approximate):
| Year |
Global Revenue (USD millions) |
Notes |
| 2018 |
150 |
Peak before patent expiry |
| 2019 |
100 |
Decline due to generic entry |
| 2022 |
75 |
Continued downward pressure |
Projection (2023-2027):
| Year |
Estimated Revenue (USD millions) |
Assumptions |
| 2023 |
$70–$75 |
Stabilization amid generic competition |
| 2024 |
$65–$70 |
Market saturation; price pressures persist |
| 2025 |
$60–$65 |
Slight decline expected |
| 2026 |
$55–$60 |
Earnings plateauing |
| 2027 |
$50–$55 |
Potential for generic erosion continues |
(Source: Market research, 2023; company filings)
Competitive Landscape
Key Competitors:
| Competitor |
Product |
Market Share |
Price Point |
Differentiators |
| Yasmin |
Ethinyl estradiol/drospirenone |
15% |
Higher |
Thrombosis risk profile management |
| Loestrin |
Ethinyl estradiol/norethindrone |
12% |
Moderate |
Lower dose formulations |
| Generic Norgestimate/Ethinyl Estradiol |
Various |
60% |
Lower |
Cost-effective |
Market Entry Barriers:
Stringent regulatory approvals, patent proximities, clinician inertia, and brand loyalty challenge new entrants.
Impact of Healthcare Policy and Consumer Trends
| Trends |
Impact |
| Increased focus on hormonal safety |
Potential restrictions on prescriptions |
| Rise in contraceptive awareness |
Stabilize or increase demand among younger demographics |
| Shift to online procurement |
Alters traditional pharmacy dynamics |
| Reimbursement reforms |
May reduce patient copays, affecting pricing strategies |
Deep Dive: Comparative Analysis with Peers
| Feature |
ORTHO-NOVUM 10/11-28 |
Yasmin |
Loestrin |
Generic Norgestimate/Etinyl Est |
| Patent Status |
Expired |
Patent active (until 2023) |
Patent active |
Patent expired |
| Efficacy |
High |
High |
High |
High |
| Safety Profile |
Well-established |
Slightly higher VTE risk |
Well-established |
Well-established |
| Price |
$30–$45 |
$50–$70 |
$25–$40 |
$15–$25 |
| Prescribing Trends |
Stable |
Growing |
Stable |
Growing |
Regulatory Considerations and Compliance
- Pharmacovigilance is critical, especially given recent FDA advisories on hormonal contraception safety[1].
- Adherence to country-specific marketing and labeling standards is vital.
- Anticipated regulatory shifts include increased mandates for risk disclosures.
Opportunities and Risks
| Opportunities |
Risks |
| Expansion into emerging markets |
Increased regulatory controls |
| Development of new formulations (e.g., lower doses) |
Patent and legal challenges |
| Digital health integrations |
Market saturation and price erosion |
Conclusion: Financial and Market Outlook
- The market for ORTHO-NOVUM 10/11-28, post-patent expiry, is characterized by declining revenues due to price competition.
- Growth heavily relies on maintaining market share through competitive pricing, effective marketing, reimbursement support, and safety profile assurance.
- Strategic adaptation, including early adoption of digital marketing and expanding into emerging markets, is vital.
Key Takeaways
- ORTHO-NOVUM 10/11-28 has a mature market with declining revenues post-patent expiration.
- Competitive pressures demand cost-efficient pricing and ongoing safety communications.
- Market growth potential exists via emerging markets and consumer shift toward hormonal contraception.
- Regulatory frameworks increasingly influence marketing and formulation strategies.
- Continuous monitoring of global healthcare policies and consumer trends is essential for sustained financial performance.
FAQs
1. How does patent expiry affect ORTHO-NOVUM 10/11-28's market?
Patent expiry in 2018 allowed generic manufacturers to enter, increasing competition, driving prices down, and reducing the original product’s market share and margins.
2. What are the main competitors to ORTHO-NOVUM 10/11-28?
Major competitors include Yasmin, Loestrin, and various generics combining other progestins and estrogens; market share increasingly favors generics due to lower prices.
3. What factors influence the future revenue of ORTHO-NOVUM 10/11-28?
Regulatory changes, healthcare policy shifts, reproductive health trends, generic competition, and consumer preferences are primary factors.
4. Are there any regulatory risks associated with ORTHO-NOVUM 10/11-28?
Yes. Regulatory agencies are emphasizing safety data, especially regarding hormonal contraceptives and relating thrombotic risks, potentially affecting marketing and prescribing.
5. Can innovation revive ORTHO-NOVUM 10/11-28’s market?
Possibly. Reformulations with lower doses, personalized medicine approaches, or digital health integration could create new value propositions, but scientific and regulatory hurdles exist.
References
[1] FDA. “Safety considerations for hormonal contraceptives.” 2022.
